Fluidic Sciences acquires business and assets of Sphere Bio

Fluidic Sciences has purchased the business and assets of Sphere Bio Ltd. The transaction creates a powerful, complementary technology suite that enables researchers to seamlessly traverse cellular function and molecular binding, accelerating biotherapeutic discovery and development.

Sphere Bio’s proprietary picodroplet systems and Cyto‑Mine^® Chroma multiplexing platform deliver rapid, high‑fidelity, single‑cell screening, isolation, and monoclonality assurance. These capabilities align with Fluidic Sciences’ Microfluidic Diffusional Sizing (MDS) platform — an immobilization‑free, in‑solution approach that measures binding affinity (Kd), stoichiometry, and concentration directly in complex matrices — to offer a uniquely integrated workflow from cell to molecular mechanism.

Fluidic Sciences will integrate Sphere Bio’s teams over the coming months, aligning roadmap priorities and maintaining uninterrupted customer support. In the immediate term, both brands will continue in market; a unified solutions roadmap and cross‑workflow application notes will follow.

Dr. James Wilkinson, CEO, Fluidic Sciences, commented, “By bringing Sphere Bio into Fluidic Sciences, we’re pairing high‑throughput functional cell screening with definitive in‑solution interaction measurements — creating an end‑to‑end workflow that accelerates discovery and de‑risks development”

“We are excited to combine our single-cell expertise with Fluidic Sciences’ in-solution technologies to deliver integrated solutions that accelerate discovery. Within Fluidic Sciences, we’ll continue innovating and expanding applications for picodroplets and Cyto‑Mine Chroma — now connected to powerful in‑solution biophysics,” said Richard Hammond, CTO, Sphere Bio.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>